Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Skyline Medical Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements
MINNEAPOLIS , Jan. 11, 2018 (GLOBE NEWSWIRE) -- Skyline Medical Inc (NASDAQ:SKLN) (“Skyline” or the “Company”), producer of the FDA -approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, today announced that it received a letter from the Listing Qualifications Department
View HTML
Toggle Summary Helomics® Corporation Announces the appointment of Dr. Marc Malandro to its Advisory Board, providing strategic insights for the Skyline Medical – Helomics Joint Venture
PITTSBURGH , Jan. 10, 2018 (GLOBE NEWSWIRE) -- Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, today announced the addition of Marc Malandro PhD, CLP, RTTP,
View HTML
Toggle Summary Skyline Medical Announces Pricing of Firm Commitment Public Offering of Common Stock and Warrants
MINNEAPOLIS , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Skyline Medical Inc. (NASDAQ:SKLN) (“Skyline” or “the Company”), producer of the FDA -approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, today announced the pricing of a firm commitment underwritten public offering of
View HTML
Toggle Summary Skyline Medical Provides Sales Update on the STREAMWAY System
Ten STREAMWAY units sold in 2017; six unit sales booked in January 2018 MINNEAPOLIS , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Skyline Medical Inc . (NASDAQ:SKLN) (“Skyline” or the “Company”), today announced an update on commercial activities for its FDA -approved STREAMWAY ® System for automated,
View HTML
Toggle Summary Helomics® Corporation and Ariel Precision Medicine, Inc. sign a services agreement to Advance Clinical Genomics in Precision Medicine Applications
PITTSBURGH , Dec. 20, 2017 (GLOBE NEWSWIRE) -- Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotechnology industries, and Ariel Precision Medicine, Inc.
View HTML
Toggle Summary Skyline Medical and Helomics expand into Next Generation Sequencing for Personalized Medicine
NGS platform to generate additional clinical data to build out the Skyline-Helomics D-CHIP bioinformatics platform MINNEAPOLIS , Dec. 20, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc . (NASDAQ:SKLN) (“Skyline” or the “Company”), producer of the FDA -approved STREAMWAY® System for automated,
View HTML
Toggle Summary Skyline Medical Acquiring up to 25% Equity Stake in Helomics Corporation, a Precision Diagnostics Company
MINNEAPOLIS , Dec. 19, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc . (NASDAQ:SKLN) (“Skyline” or the “Company”), producer of the FDA -approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, today announced it has agreed to purchase an equity stake in Helomics Corporation
View HTML
Toggle Summary Skyline Medical Issues Letter to Shareholders
MINNEAPOLIS , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc . (NASDAQ:SKLN) (“Skyline” or the “Company”), producer of the FDA -approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, today issued a press release with the following letter to shareholders.
View HTML
Toggle Summary Skyline Medical Inc. Announces the Completion of Private Placement for Gross Proceeds of $1,300,000
BOCA RATON, Fla. , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Dawson James Securities, Inc. in conjunction with Skyline Medical Inc. closed a private placement of a newly created series of preferred stock designated as “Series C Convertible Preferred Stock” with a New York -based Family Office.
View HTML
Toggle Summary Skyline Medical and Helomics Announce a Joint Strategic Partnership with GLG Pharma
Companies to form a partnership for cell capture, culture and drug screening for ovarian and breast cancer patients MINNEAPOLIS , Nov. 28, 2017 (GLOBE NEWSWIRE) -- GLG Pharma , a Jupiter, Florida company developing precision medicines that target the Signal Transducer and Activator of Transcription
View HTML